ZNF683 marks a CD8+ T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome

ZNF683 标记一种 CD8+ T 细胞群,该细胞群与 Richter 综合征患者接受抗 PD-1 治疗后的抗肿瘤免疫相关。

阅读:2
作者:Erin M Parry ,Camilla K Lemvigh ,Stephanie Deng ,Nathan Dangle ,Neil Ruthen ,Binyamin A Knisbacher ,Julien Broséus ,Sébastien Hergalant ,Romain Guièze ,Shuqiang Li ,Wandi Zhang ,Connor Johnson ,Jaclyn M Long ,Shanye Yin ,Lillian Werner ,Annabelle Anandappa ,Noelia Purroy ,Satyen Gohil ,Giacomo Oliveira ,Pavan Bachireddy ,Sachet A Shukla ,Teddy Huang ,Joseph D Khoury ,Beenu Thakral ,Michael Dickinson ,Constantine Tam ,Kenneth J Livak ,Gad Getz ,Donna Neuberg ,Pierre Feugier ,Peter Kharchenko ,William Wierda ,Lars Rønn Olsen ,Nitin Jain ,Catherine J Wu

Abstract

Unlike many other hematologic malignancies, Richter syndrome (RS), an aggressive B cell lymphoma originating from indolent chronic lymphocytic leukemia, is responsive to PD-1 blockade. To discover the determinants of response, we analyze single-cell transcriptome data generated from 17 bone marrow samples longitudinally collected from 6 patients with RS. Response is associated with intermediate exhausted CD8 effector/effector memory T cells marked by high expression of the transcription factor ZNF683, determined to be evolving from stem-like memory cells and divergent from terminally exhausted cells. This signature overlaps with that of tumor-infiltrating populations from anti-PD-1 responsive solid tumors. ZNF683 is found to directly target key T cell genes (TCF7, LMO2, CD69) and impact pathways of T cell cytotoxicity and activation. Analysis of pre-treatment peripheral blood from 10 independent patients with RS treated with anti-PD-1, as well as patients with solid tumors treated with anti-PD-1, supports an association of ZNF683high T cells with response.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。